

The 23rd Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies

April 21 – 23, 2023

Friday, April 21, 2023

12:00 pm **Registration Opens**

12:50 pm Welcome and Introductions: Therese Hennig, MPAS, PA-C

Session 1: ABC's of Hematologic Malignancies

Moderator: Therese Hennig, MPAS, PA-C

12:55 pm Pre-session Survey

1:00 pm Approach to Diagnosis of Blood Dyscrasias
Scott Winkel, MHS, MSPH, PA-C

1:40 pm Personalized Therapeutics: Risk Stratification in Treatment Selection for AML
Donna Adams, NP

2:00 pm Personalized Therapeutics: Risk Stratification in Treatment Selection for Multiple Myeloma
Emily Sellars, RN, MSN, ANP-C

2:20 pm **Break and Product Theater #1**

3:00 pm What's all the Fuss with CAR-T? Does One Size Fit All?
Krista Rowe Nichols, RN, MSN, AOCNS

3:30 pm Transplantation Overview
Tanya Helms, PA-C, R.Ph

4:00 pm Decision Making for Individual Patients: CAR-T vs. Transplant
Ahmed Galal, MD

4:30 pm Medication-related Osteonecrosis of the Jaw (MRONJ): Update and Management Strategies
Katharine Ciarrocca, DMD, MSED

5:10 pm **Closing Remarks**

Saturday, April 22, 2023

7:00 – 7:50 am **Registration and Breakfast**

Session 2: Leukemias / MDS / MPD

Moderator: Harry Erba, MD, PhD

7:55 am Welcome and Pre-Session Survey

8:00 am **Keynote: First Things First – And Last: Onco-Primary Care in Heme Malignancies**
Kevin Oeffinger, MD

8:45 am Optimizing Outcomes for ALL: The Role of Risk Stratification and Assessment of Minimal Residual Disease
Harry Erba, MD, PhD

9:10 am **Case Presentation and Debate:** Incorporating Transplant into the Management of Standard Risk ALL Optimized Outcomes
Emily Curran, MD (Univ. of Cinn.) vs. Patrick Stiff, MD (Loyola)

10:00 am **Break and Product Theater #2**

10:40 am **Case Presentation and Debate:** The Evolving “Standard of Care” for Myelofibrosis Optimizes Outcomes and Minimizes Toxicities
Lindsay Rein, MD vs. Mitch Horwitz, MD

11:30 am **Case Presentation and Debate:** First Generation Agents Offer the Best Overall Outcomes in FLT3 Mutated AML
Richard Stone, MD (Harvard) vs. Harry Erba, MD, PhD

12:30 - 1:25 pm **Lunch and Time with Exhibitors**

Session 3: Myeloma and Plasma Cell Dysplasias

Moderator: Cristiana Chase, DO

1:25 pm Pre-Session Survey

1:30 pm **The Evolving Landscape of MM Treatment**
Cristiana Chase, DO

1:45 pm **Debate:** Transplantation Plays a Critical Role in Managing MM
Clifton Mo, MD (Harvard) vs. Taewoong Choi, MD

2:30 pm **Debate:** Approach to Relapse After Response
Cristiana Chase, DO vs. Yubin Kang, MD

3:15 pm **Break and Product Theater #3**

3:55 pm **Clinical Round Table with Case Presentation: AL Amyloidosis**
Cristiana Chase, DO, Clifton Mo, MD (Harvard) and Yubin Kang, MD

4:45 pm **Monoclonal Gammopathy of Renal Significance: Diagnosis and Next Steps**
Scott Winkel, MHS, MSPH, PA-C

5:00 pm **Monoclonal Gammopathy of Renal Significance: Treatments**
Taewoong Choi, MD

5:15 pm Post Session Survey and Adjourn

Sunday, April 23, 2023

7:00am – 7:45am **Registration and Breakfast and Product Theater #4**

7:50 am Welcome: Danielle Brander, MD

7:55 am Pre-Session Survey

Session 4: Lymphocytic Malignancies

Moderator: Danielle Brander, MD

8:00 am **Case Presentation and Debate:** Combination Regimes are Superior to Monotherapy with Novel Therapeutics in CLL
Bill Wierda, MD (MD Anderson) vs. Andrea Sitlinger, MD

8:45 am **Case Presentation and Roundtable:** Use of BTKi Should be Optimized Before Moving to Alternatives
Danielle Brander, MD, Andrea Sitlinger, MD, Bill Wierda, MD

9:30 am **Case Presentation and Debate:** Is CAR-T a Better Option than Auto-Transplant in Recurrent DLBCL Role of Transplant in Lymphoma, in the Era of CAR-T; Identifying Best Candidates
Mazyar Shadman, MD, MPH (Fred Hutch) vs. Ahmed Galal, MD

10:15 am The Future of CAR-T
Ahmed Galal, MD

10:35 am Break

11:00 am **Case Presentation and Debate:** Autologous Transplant in T-Cell Lymphoma
Basem William, MD, MRCP, FACP vs. Matthew McKinney, MD

11:40 am **Molecular Tumor Board:** Individualized Therapy in Heme Malignancies: Using Genetic and Molecular Profiling to Optimize Therapy
Matthew McKinney, MD

12:20 pm Adjourn